Myasthenia gravis trials in Netherlands

In Netherlands 8 Also abroad 123

8 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients with Myasthenia Gravis
Where
Leiden
Age
18 years and over
People
59 worldwide
Run by
NMD Pharma A/S
See details and how to join2023-507539-40-00 · EU 2023-507539-40-00
Phase 2/3Taking people
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
Where
Leiden
Age
2 years to 17 years
People
12 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05265273 · EU 2022-502539-21-00
Phase 2Taking people
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
Where
Leiden
Age
18 years and over
People
40 worldwide
Run by
argenx
See details and how to joinNCT07673627 · EU 2025-522939-33-00
Phase 2/3Enrolling by invitation
Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
Where
Leiden
Age
2 years to 18 years
People
12 worldwide
Run by
argenx
See details and how to joinNCT05374590 · EU 2023-507379-23-00
Phase 2/3Taking people
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
Where
Leiden
Age
2 years to 17 years
People
12 worldwide
Run by
argenx
See details and how to joinNCT06392386 · EU 2023-506159-12-00
Phase 2Taking people
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Where
Leiden
Age
18 years and over
People
70 worldwide
Run by
argenx
See details and how to joinNCT07284420 · EU 2025-522492-28-00
Phase 2Taking people
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
Where
Leiden
Age
18 years and over
People
84 worldwide
Run by
NMD Pharma A/S
See details and how to joinNCT06414954
No phaseTaking people
Capturing Key MG-symptoms Using Smartphone Recordings.
Where
Leiden
Age
18 years and over
People
225
Run by
Leiden University Medical Center
See details and how to joinNCT06743490